2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Gene Editing, Treatment Considerations, Biological Therapies, Gene Therapy, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Pediatric, Animal Model
PAPER

3191 Universal correction of telomere biology disorder TINF2 hotspot mutations with prime editing

Nozomu Kawashima, MD, PhD, Sébastien Levesque, PhD2, GueHo Hwang, PhD3, Jing Zeng, MD4, Vasil T Toskov, MD5, Timothy Barry, PhD6, William Mannherz, BS7, Luke Homfeldt8, Basheer Becerra9, Vivien Schoonenberg, PhD10, Luca Pinello, PhD11, Suneet Agarwal, MD PHD12, Daniel E. Bauer, MD, PhD13
1 Boston Children's Hospital, Boston, Massachusetts, United States
2 Boston Children's Hospital, Boston, Massachusetts, United States, Université Laval, Quebec City, Quebec, Canada
3 Boston Children's Hospital, Boston, Massachusetts, United States, Hanyang University, Seoul, Korea, Rep. of South
4 Boston Children's Hospital, Boston, Massachusetts, United States
5 Boston Children's Hospital, Boston, Massachusetts, United States
6 Boston Children's Hospital, Boston, Massachusetts, United States
7 Boston Children's Hospital, Boston, Massachusetts, United States
8 Boston Children's Hospital, Boston, Massachusetts, United States
9 Boston Children's Hospital, Boston, Massachusetts, United States
10 Boston Children's Hospital, Boston, Massachusetts, United States
11 Massachusetts General Hospital, Boston, Massachusetts, United States
12 Boston Children's Hospital, Boston, Massachusetts, United States
13 Boston Children's Hospital, Boston, Massachusetts, United States

Telomere biology disorders (TBDs) are rare inherited disorders that include bone marrow failure, myeloid malignancy predisposition, and extrahematologic features. TINF2 heterozygous pathogenic variants clustering within a narrow hotspot region in exon 6 are associated with extremely short telomeres and severe, early-onset disease. We hypothesized that a single method to replace this entire mutation cluster with a DNA sequence encoding the reference protein sequence could provide a universal therapeutic strategy for TINF2-associated TBD. To achieve this, we developed a novel prime editing-based platform, termed prime assembly (PA), that enables targeted replacement of medium-to-large sized DNA sequences without generating DNA double-strand breaks (DSBs). PA utilizes paired prime-editing guide RNAs (pegRNAs) and prime editor-mediated synthesis of complementary 3′ flaps to direct site-specific integration of exogenous DNA donors. To prevent donor and flap hybridization to endogenous genomic sequences, we aimed to recode a 106-nt region of exon 6 using synonymous codon substitutions. We tested dsDNA donors, paired complementary ssDNA donors, or single ssDNA donors with Gibson assembly-inspired 3′ overhangs. The 3′ overhang of the top donor was designed to be reverse-complementary to the reverse flap generated by prime editing, whereas the 3′ overhang of the bottom donor was reverse-complementary to the forward flap. Electroporation of K562 and HEK293T cells with plasmids encoding prime editor and two pegRNAs achieved 30% recoding efficiency across pegRNA designs. Paired synthetic ssDNA donors containing three phosphorothioate linkages at both termini and 5′ phosphorylation produced the highest editing efficiency, reaching 33.1% in K562 cells. Varying flap length 20–56 nt had minimal impact on editing efficiency. Amplicon sequencing identified several classes of unintended edits, including flap integrations with and without indels. Transient treatment with the DNA-PK inhibitor AZD7648 alone or in combination with the Polθ inhibitor PolQi1 to inhibit nonhomologous end joining and microhomology-mediated end joining increased prime assembly efficiency as well as the ratio of precise-to-imprecise PA products by 4.1-fold and 8.5-fold, up to 30.9% and 40.6% precise PA and 9.7% and 6.2% imprecise edits, respectively. In–out PCR followed by sequencing demonstrated 97.8% and 98.8% precise 5′ and 3′ donor–target junctions, respectively. We developed Donor-Seq, a donor-anchored integration profiling method, which detected no recurrent guide-dependent off-target donor integration events despite recovering hundreds of thousands of unique on-target integrations. To determine whether PA could operate in non-dividing cells, we arrested cells in G1 using the CDK4/6 inhibitor palbociclib. Palbociclib decreased PA efficiency by only 1.5-fold, indicating PA remains active in non-proliferating cells. We further simplified the system by designing partially overlapping long pegRNA-encoded flaps that eliminated the need for an exogenous donor. Although standard pegRNAs produced little detectable editing, incorporation of the tevopreQ1 RNA stabilization motif (epegRNA) increased precise editing to 19.5% with 3.8% unintended modification in the absence of small-molecule inhibitors. Given the intrinsic fitness defect of HSCs in TBDs associated with telomere attrition and given that numerous cases of somatic reversion have been described in TBDs, including with TINF2-associated TBD, we hypothesize that these observed frequencies of precise editing may be sufficient to exceed a minimal therapeutic threshold. Collectively, we present highly efficient and specific, DSB–free, universal genome editing approaches for TINF2-associated TBD that are active in non-proliferating cells. These findings establish a foundation for the development of genetic therapies targeting hematologic and extrahematologic manifestations of TBDs.

Nozomu Kawashima, MD, PhD: No relevant conflicts of interest to declare.